title: Metastasis Risk Reduction Related with Beta-Blocker Treatment in Mexican Women with Breast Cancer.
abstract: BACKGROUND
  Breast Cancer (BCa) is the most common malignant tumour in Mexican women. In BCa, several studies have linked β2-adrenergic receptor activation with increased tumour growth and progression as related with Epinephrine-NorEpinephrine (E-NE) stimulation. The aim of this study was to describe Beta-Blocker (BB) treatment related with reduction of the risk of metastasis in Mexican patients with BCa.
  
  
  METHODS
  We collected data of 120 patients seen at the High-Specialty Naval General Hospital in Mexico City (HOSGENAES), all of these with a histopathological diagnosis of BCa. Four groups of patients were divided as follows: without Systemic Arterial Hypertension (SAH); with SAH treatment with non-selective BB; with SAH treatment with selective BB, and with SAH treatment with other antihypertensive drugs. Chi-square, Mantel- Haenszel, Student t, and ANOVA tests were performed for data analysis.
  
  
  RESULTS
  On average, patients were 54.8±11.8 years of age. Risk factors such as smoking and consuming alcohol exhibited a frequency of 33 and 36.5% respectively. Clinical stages III- IV were found in 50% of patients, while, 30% of patients had arterial hypertension (n=29 and N=96, respectively) and 17.5% used BB. One hundred percent of patients with arterial hypertension treated with BB for β1 - and β2 -adrenergic-receptors did not present metastasis globally, but patients treated with β1 BB presented 30% of metastasis while patients treated with no BB or without SAH had around 70% of metastasis.
  
  
  CONCLUSIONS
  In Mexican patients with BCa and SAH treated with non-selective (β1- and β2-adrenergic receptors) BB, a decrease in the risk for metastasis was observed at the time of diagnosis.
authors.affiliation: Naval Medical School, Secretary of the Navy, Mexico E-mail : cindimiel@hotmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Parada-Huerta
authors.forename: Tp
authors.initials: T
authors.lastname: Alvarez-Dominguez
authors.forename: R
authors.initials: R
authors.lastname: Uribe-Escamilla
authors.forename: Jf
authors.initials: J
authors.lastname: Rodriguez-Joya
authors.forename: Ja Diaz
authors.initials: JD
authors.lastname: Ponce-Medrano
authors.forename: S
authors.initials: S
authors.lastname: Padron-Lucio
authors.forename: A
authors.initials: A
authors.lastname: Alfaro-Rodriguez
authors.forename: C
authors.initials: C
authors.lastname: Bandala
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008207:Lymphatic Metastasis; D008800:Mexico; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D040242:Risk Reduction Behavior
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents